We are live on
!
Find out more
FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
1-Year Est. Return
44.84%
This Fund
S&P 500
This Quarter
Est. Return
-27.19%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$189M
AUM Growth
-$81.5M
(-30%)
Cap. Flow
-$1.4M
Cap. Flow
% of AUM
-0.74%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
2
Increased
3
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$9.76M |
| 2 |
Twist Bioscience
TWST
|
+$1.61M |
| 3 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$1.48M |
| 4 |
Natera
NTRA
|
+$1.26M |
| 5 |
EPZM
Epizyme, Inc
EPZM
|
+$958K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AIMT
Aimmune Therapeutics
AIMT
|
+$8.59M |
| 2 |
Denali Therapeutics
DNLI
|
+$5.43M |
| 3 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$1.36M |
| 4 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
+$536K |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$533K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
| $71M | 37.63% |
2,968,649
-332,148
| -10% | -$8.59M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $60.4M | 32% |
1,672,714
+207,965
| +14% | +$9.76M |
|
|
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
| $16.3M | 8.62% |
1,586,220
| – | – |
|
4
Insmed
INSM
$23.2B
| $12.7M | 6.73% |
967,636
| – | – |
|
|
EPZM
5
DELISTED
Epizyme, Inc
EPZM
| $9.6M | 5.09% |
1,557,864
+125,500
| +9% | +$958K |
|
|
XLRN
6
DELISTED
Acceleron Pharma
XLRN
| $9.13M | 4.84% |
209,602
-10,666
| -5% | -$533K |
|
|
ADAP
7
DELISTED
Adaptimmune Therapeutics
ADAP
| $4.03M | 2.13% |
700,000
+200,000
| +40% | +$1.48M |
|
|
BDSI
8
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $2.95M | 1.56% |
796,733
-152,500
| -16% | -$536K |
|
|
9
Twist Bioscience
TWST
$5.32B
| $1.68M | 0.89% |
+72,849
| New | +$1.61M |
|
|
10
Natera
NTRA
$37.2B
| $964K | 0.51% |
+69,045
| New | +$1.26M |
|
|
11
Denali Therapeutics
DNLI
$3.77B
| – | – |
-250,000
| Closed | -$5.43M |
|
|
SGMO
12
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-80,500
| Closed | -$1.36M |
|
Similar funds
AG
SAM
AC
QI
TAAM
NAM
MSKCC
BRC
Foresite Capital Management II's Q4 2018 Portfolio in Review
As of Q4 2018, Foresite Capital Management II held 12 positions worth $189M, down 30% from $270M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management II's Q4 2018 filing shows 2 new, 3 increased, 3 reduced and 2 closed positions. Its largest new stake was Twist Bioscience: 72,849 shares worth $1.68M. The largest sale was Aimmune Therapeutics, an estimated $8.59M.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 33% a quarter earlier.
- Foresite Capital Management II's largest Q4 2018 buy was Twist Bioscience: 72,849 shares worth $1.68M.
- Foresite Capital Management II added most to Aerie Pharmaceuticals in Q4 2018, an estimated $9.76M increase.
- Foresite Capital Management II's biggest Q4 2018 reduction was Aimmune Therapeutics, cutting an estimated $8.59M.
- Foresite Capital Management II fully exited Denali Therapeutics in Q4 2018, selling an estimated $5.43M.
- Foresite Capital Management II's ten largest holdings make up 100% of its $189M portfolio in Q4 2018.
- Foresite Capital Management II opened 2 new positions and closed 2 in Q4 2018.
- Foresite Capital Management II's portfolio value fell 30% quarter-over-quarter to $189M.
Based on Foresite Capital Management II's 13F filing for Q4 2018, filed 13 Feb 2019.